WALTHAM, Mass., January 04, 2023--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a person successful the expanding tract of antibody-drug conjugates (ADCs) for the attraction of cancer, contiguous announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.
"Following the caller support and motorboat of ELAHERE™ (mirvetuximab soravtansine-gynx), we person transitioned to a fully-integrated oncology institution pursuing the planetary improvement and commercialization of our portfolio of caller ADCs. As we look to grow ELAHERE's statement and beforehand our pipeline, it is indispensable that we strategically align our research, development, clinical, medical, and regulatory affairs activities astatine a local, regional, and planetary level," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "I americium delighted to invited Mike to our Executive Committee to pb the adjacent signifier of maturation for these activities. Mike brings implicit 30 years of acquisition successful the discovery, planetary development, and support of transformative crab therapies. His beardown world and manufacture relationships and cognition of the scientific, medical, and regulatory scenery volition beryllium integral to the businesslike and effectual transportation of our portfolio to markets astir the world."
Most recently, Dr. Vasconcelles has served arsenic a Senior Advisor to the Life Sciences squad astatine Frazier Healthcare Partners. Prior to that, helium was the Chief Medical Officer and Head of the Medical and Scientific Organization astatine Flatiron Health, a wellness tech institution focused connected accelerating crab probe and improving diligent care. Before joining Flatiron, Dr. Vasconcelles served arsenic Chief Medical Officer astatine Unum Therapeutics, a compartment and cistron therapy institution processing autologous engineered T-cell products for the attraction of cancer. He besides spent respective years astatine Takeda/Millennium, wherever helium was Senior Vice President and Head of the Oncology Therapy Area Unit. Earlier successful his career, Dr. Vasconcelles was Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology astatine Genzyme Corporation, wherever helium was liable for objective improvement of the transplant and oncology portfolio and a subordinate of the Transplant and Oncology Business Unit absorption team. Following Sanofi's acquisition of Genzyme, helium joined Sanofi Oncology arsenic Head of Personalized Medicine and Companion Diagnostics. Dr. Vasconcelles serves arsenic a non-executive manager of Molecular Partners AG and Magenta Therapeutics, Inc., a Board subordinate of the Personalized Medicine Coalition and the Eastern New England American Cancer Society, and a subordinate of respective Scientific Advisory Boards wrong the biopharmaceutical industry. From 1996-2021, helium was a module subordinate astatine Harvard Medical School and an subordinate doc astatine Brigham and Women's Hospital and Dana-Farber Cancer Institute. Dr. Vasconcelles received some his BA and MD from Northwestern University.
"This is an exhilarating adjacent section for ImmunoGen arsenic the Company brings its archetypal wholly-owned merchandise to market, advances its pipeline of ADCs done the clinic, and reinvigorates its early-stage find and probe efforts to thrust aboriginal growth," said Dr. Vasconcelles. "Building connected 40 years of ADC innovation, I look guardant to moving with the remainder of the ImmunoGen squad to thrust the enlargement of our level and portfolio arsenic we enactment to bring ELAHERE, and arsenic groundbreaking medicines, to patients crossed the globe."
ABOUT IMMUNOGEN
ImmunoGen is processing the adjacent procreation of antibody-drug conjugates (ADCs) to amended outcomes for crab patients. By generating targeted therapies with enhanced anti-tumor enactment and favorable tolerability profiles, we purpose to disrupt the progression of crab and connection our patients much bully days. We telephone this our committedness to TARGET A BETTER NOW™.
Learn much astir who we are, what we do, and however we bash it astatine www.immunogen.com.
ABOUT ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)
ELAHERE (mirvetuximab soravtansine-gynx) is simply a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to termination the targeted crab cells. Please spot afloat Prescribing Information, including a Boxed Warning, for ELAHERE here.
FORWARD-LOOKING STATEMENTS
This property merchandise includes forward-looking statements. These statements include, but are not constricted to, ImmunoGen's expectations related to the occurrence, timing, and result of the Company's merchandise and merchandise candidates, including, but not constricted to, the commercialized motorboat and statement enlargement of ELAHERE™ (mirvetuximab soravtansine-gynx), the planetary improvement and commercialization of caller ADCs, and the progression of early-stage find and probe efforts. Various factors could origin ImmunoGen's existent results to disagree materially from those discussed oregon implied successful the forward-looking statements, and you are cautioned not to spot undue reliance connected these forward-looking statements, which are existent lone arsenic of the day of this release. Factors that could origin aboriginal results to disagree materially from specified expectations include, but are not constricted to: the timing and result of the Company's preclinical and objective improvement processes; the difficulties inherent successful the improvement of caller pharmaceuticals, including uncertainties arsenic to the timing, expense, and results of preclinical studies, objective trials, and regulatory processes; the timing and result of the Company's anticipated interactions with regulatory authorities; the hazard that we whitethorn not beryllium capable to get capable prices and reimbursement for immoderate approved products, including the imaginable for delays oregon further difficulties for mirvetuximab; the hazard that the results of the ongoing MIRASOL proceedings whitethorn neglect to enactment afloat support of mirvetuximab and, if so, that further studies whitethorn beryllium required; risks and uncertainties associated with the standard and duration of the COVID-19 pandemic and the resulting interaction connected ImmunoGen's manufacture and business; and different factors arsenic acceptable distant successful the Company's Annual Report connected Form 10-K filed with the Securities and Exchange Commission connected February 28, 2022, Quarterly Reports connected Form 10-Q filed with the Securities and Exchange Commission connected May 6, 2022, August 1, 2022 and November 4, 2022, and different reports filed with the Securities and Exchange Commission. The forward-looking statements successful this property merchandise talk lone arsenic of the day of this property release. We undertake nary work to update immoderate forward-looking statement, whether arsenic a effect of caller information, aboriginal developments, oregon otherwise, but arsenic whitethorn beryllium required by applicable law.
View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20230104005094/en/
Contacts
INVESTOR RELATIONS
ImmunoGen
Anabel Chan
781-895-0600
anabel.chan@immunogen.com
MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com
English (US)